Does Rallies show Form 4 insider transactions for TRVI?

Yes. Rallies tracks TRVI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TRVI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRVI. It does not provide personalized investment advice.

TRVI (Trevi Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Trevi Therapeutics, Inc. Common Stock (TRVI) is a publicly traded Healthcare sector company. As of May 21, 2026, TRVI trades at $13.88 with a market cap of $1.91B and a P/E ratio of -29.24. TRVI moved +4.83% today. Year to date, TRVI is +22.18%; over the trailing twelve months it is +114.53%. Its 52-week range spans $2.36 to $16.12. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces TRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TRVI stock inside the company?

Recent TRVI insider activity includes SCIASCIA THOMAS sold 2.63K, GOOD JENNIFER L sold 5.26K, Simon Farrell sold 76.96K, Simon Farrell sold 4.35K, and GOOD JENNIFER L sold 1.84K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TRVI Key Metrics

Key financial metrics for TRVI
Metric	Value
Price	$13.88
Market Cap	$1.91B
P/E Ratio	-29.24
EPS	$-0.47
Dividend Yield	0.00%
52-Week High	$16.12
52-Week Low	$2.36
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-47.91M
Gross Margin	0.00%

Recent TRVI Insider Trades

SCIASCIA THOMAS sold 2.63K (~$17.36K) on Mar 25, 2025.
GOOD JENNIFER L sold 5.26K (~$34.62K) on Mar 21, 2025.
Simon Farrell sold 76.96K (~$517.78K) on Mar 10, 2025.
Simon Farrell sold 4.35K (~$31.10K) on Mar 10, 2025.
GOOD JENNIFER L sold 1.84K (~$5.59K) on Sep 9, 2024.

Latest TRVI News

Trevi Therapeutics Raises $162M, Extends Cash Runway into 2030 and Plans Phase 3 in IPF — May 5, 2026
Trevi to Present CORAL Analyses and Drug–Drug Interaction Data at ATS 2026 Orlando — Apr 30, 2026
Trevi Therapeutics Schedules May 7 NYC Investor Day, May 12 BofA Presentation and May 18 ATS Session — Apr 23, 2026
Trevi Therapeutics Secures $173 Million in Fully Exercised Share Offering — Apr 20, 2026
Trevi Therapeutics Secures $188M Cash Runway into 2028, Plans Two Phase III Trials — Mar 18, 2026

TRVI Analyst Consensus

8 analysts cover TRVI: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.50.

Common questions about TRVI

Who is trading TRVI stock inside the company?: Recent TRVI insider activity includes SCIASCIA THOMAS sold 2.63K, GOOD JENNIFER L sold 5.26K, Simon Farrell sold 76.96K, Simon Farrell sold 4.35K, and GOOD JENNIFER L sold 1.84K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TRVI?: Yes. Rallies tracks TRVI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TRVI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRVI. It does not provide personalized investment advice.